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Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a potentially curative treatment for multiple
myeloma (MM); however, because of high treatment-related mortality (TRM), its role is not well deﬁned.
Patients with newly diagnosed, relapsed, or primary refractory myeloma were enrolled in a randomized
phase II trial of 2 reduced-intensity conditioning regimens: ﬂudarabine 120 mg/m2 þ melphalan 100 mg/m2
(FM100) versus ﬂudarabine 120 mg/m2 þ melphalan 140 mg/m2 (FM140) before allo-HCT from related or
unrelated donors. Fifty patients underwent allo-HCT using FM100 (n ¼ 23) or FM140 (n ¼ 27) conditioning
between April 2002 and 2011. There were no signiﬁcant differences between FM100 and FM140 in time to
neutrophil engraftment (P ¼ .21), acute grade II to IV graft-versus-host disease (GVHD) (P ¼ 1.0), chronic
GVHD (P ¼ .24), response rate (P ¼ 1.0), TRM (13% versus 15%, P ¼ 1.0), median progression-free survival (PFS),
11.7 versus 8.4 months, P ¼ .12, and median overall survival (OS), 35.1 versus 19.7 months, P ¼ .38. Cumulative
incidence of disease progression in FM100 and FM140 was 43% and 70%, respectively (P ¼ .08). Recurrent
disease was the most common cause of death for both FM100 (26%) and FM140 (44%), P ¼ .24. On multivariate
analysis, disease status at allo-HCT, complete response or very good partial response (VGPR) was signiﬁcantly
associated with longer PFS (15.6 versus 9.6 months in patients with <VGPR, P ¼ .05). OS was similar across all
variables. We conclude that FM100 and FM140 may result in similar patient outcomes after allo-HCT for MM.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
The curative potential of allogeneic hematopoietic stem
cell transplantation (allo-HCT) in myeloma is attributed to
the graft-versus-myeloma effect mediated by the donor-
derived T lymphocytes [1,2]. Although allo-HCT after mye-
loablative conditioning may result in durable remission and
long-term survival, the treatment-related mortality (TRM) of
30% to 50% neutralizes any potential beneﬁt in terms of
overall survival (OS) [3,4]. Reduced-intensity conditioning
(RIC) allo-HCT offers the potential advantage of decreased
TRM of 15% or lower, while preserving the graft-versus-
myeloma effect [5]. We and others have shown that purine
analog containing nonmyeloablative chemotherapy enables
engraftment of allogeneic hematopoietic progenitor cells
(HPC) in patients considered ineligible for myeloablative
therapy because of age or medical illness [6-8]. We havedgments on page 1457.
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13.07.008previously shown that RIC allo-HCT is associated with
durable remission and survival in selected patients with
relapsed or refractory multiple myeloma (MM) [9]. In that
study of heavily pretreated patients, progression-free
survival (PFS) and OS at 2 years were 19% and 32%, respec-
tively, and 24% of patients were still alive after a median
follow-up of 27 months. Most patients received melphalan
140 mg/m2, which was tolerated well. Badros et al. used
melphalan 100 mg/m2 as a preparative regimen for allo-HCT
in myeloma patients who relapsed after an autologous HCT
[10]. Engraftment occurred in 15 of 16 patients, and 1-year
TRM was <20%. However, the optimal dose of melphalan
before allo-HCT is not clearly deﬁned. We hypothesized that
a lower dose of melphalan would result in lower toxicity
without compromising the engraftment or disease control.
Rituximab (Rituxan, Genentech Inc., South San Francisco,
CA) is a humanizedmonoclonal antibody directed at the CD20
antigen, which is present on 10% to 15% of myeloma cells [11].
In a report by Kebriaei et al.,grade II acute graft-versus-host
disease (GVHD) was seen in 17% of patients after addition of
rituximab to a total body irradiationecontaining conditioning
regimen, which was lower than the 37% seen in historicalTransplantation.
Q. Bashir et al. / Biol Blood Marrow Transplant 19 (2013) 1453e14581454controls [12]. This reduction inGVHD rate has beenpostulated
to be due to the depletion of antigen-presenting B cells that
may playa role in the developmentof acute and chronicGVHD
[12,13]. Based on this observation, rituximabwas added to the
conditioning regimen in the last 23 patients.
In this randomized phase II trial, we compared 2 RIC
regimens: (1) ﬂudarabine þmelphalan 140 mg/m2 (FM140),
and (2) ﬂudarabine þ melphalan 100 mg/m2 (FM100), in
extensively pretreated myeloma patients undergoing allo-
HCT. The primary aim of the study was to evaluate whether
a lower dose of melphalan would result in less toxicity and
less GVHD with equal engraftment rates and disease control.
MATERIALS AND METHODS
Patients
Patients with newly diagnosed, relapsed, or primary refractorymyeloma
were enrolled between April 2002 and April 2011. The inclusion criteria
were the following: age70, Zubord performance status<2, left ventricular
ejection fraction >40% with no uncontrolled arrhythmia or unstable cardiac
disease, corrected QT interval <470 ms, adequate pulmonary function
(Forced expiratory volume (FEV1), Forced vital capacity (FVC), and Diffusing
capacity of lung for carbon monoxide (DLCO)-corrected for hemoglobin
>40%) with no symptomatic pulmonary disease, serum creatinine 2.0 mg/
dL, serum bilirubin 3 times and Serum glutamic-pyruvic transaminase
(SGPT) 4 times upper normal limit, no evidence of chronic active hepatitis
or cirrhosis, no effusion or ascites1 liter before drainage, HIV negative, and
not pregnant. All patients gave written informed consent according to the
institutional guidelines, and the clinical trial was approved by the M.D.
Anderson Cancer Center institutional review board (ClinicalTrials.gov
identiﬁer: NCT00505895).
Hematopoietic Progenitor Cell Collection
Allogeneic HPCs from bone marrow or peripheral blood [14] were
procured using standard techniques. Brieﬂy, bone marrow was aspirated
from the posterior iliac crest under general anesthesia, with a target of at
least 2  108 nucleated cells/kg of patient weight [15]. HPCs from peripheral
blood were obtained through apheresis after mobilization with 10 mg/kg
body weight ﬁlgrastim (granulocyte colony-stimulating factor, Neupogen,
Amgen, Inc., Thousand Oaks, CA) per day [16]. HPCs frommatched unrelated
donors (MUD) were obtained through the National Marrow Donor Program
(NMDP).
Preparative Regimens and Supportive Care
The FM100 regimen consisted of ﬂudarabine 30 mg/m2 intravenously
daily, given over 30 minutes on days 4, 3, 2, and 1. Melphalan was
dosed at 100 mg/m2 intravenously over 20 minutes on day 1. The FM140
regimen consisted of the same dose of ﬂudarabine; however, the dose of
melphalan was 140 mg/m2 intravenously over 20 minutes on day 1. Rit-
uximab 375 mg/m2 intravenously was administered weekly for 4 doses on
days 5, þ2, þ9, and þ16 in the last 23 patients (FM100, n ¼ 9; FM140, n ¼
14) to reduce the risk of GVHD [12]. All patients who received HPCs from
MUDs also received antithymocyte globulin (ATG) 1.5 mg/kg infused over 6
hours for 3 days (day3,2, and1). AllogeneicHPCswere infused on day 0.
GVHD prophylaxis consisted of tacrolimus (Fujisawa Healthcare, Deer-
ﬁeld, IL) and minimethotrexate [17]. Tacrolimus was started on day 1 and
administered for 6 to 9 months if the patient remained free of GVHD. Dose
was adjusted to maintain the level between 5 ng/mL and 10 ng/mL. Meth-
otrexate 5 mg/m2 intravenously was given on days 1, 3, 6, and 11. All
supportive care measures were according to standard institutional guide-
lines as previously described [18].
HLA Typing
High-resolution allele levelHLA typing forHLA-A, -B, -C, -DRB1, and -DQB1
was used to match donorerecipient pairs, as previously described [19].
Engraftment
Neutrophil engraftmentwas deﬁned as the ﬁrst of 3 consecutive days that
the absolute neutrophil count exceeded .5  109/L of blood. Platelet
engraftmentwas deﬁned as the ﬁrst of 7 consecutive days when the platelet
count exceeded 20  109/L, without requiring platelet transfusions.
Response Criteria and Outcome
Response, disease progression, and relapse were deﬁned according to
the International Myeloma Working Group uniform response criteria [20].
The primary endpoints were response rate, engraftment, and 100-day TRM.The secondary outcome measures were PFS, OS, acute GVHD, and grade III-
IV toxicity. GVHD occurring any time after day 90 post-transplantation was
considered chronic GVHD; otherwise, it was considered acute GVHD.
Toxicity was graded according to the National Cancer Institute Common
Terminology Criteria (version 3.0, Bethesda, MD). PFS was the time from the
day of allo-HCT to progression or time the patient was last known to be alive
without disease progression. OS was time from the day of allo-HCT to death
or the time last known to be alive. Death from any cause other than relapse
was classiﬁed as TRM. High-risk chromosomal abnormalities were deﬁned
as the following: del 13 or hypodiploidy on conventional cytogenetics, and
t(4;14), t(14;16), or del17p on ﬂuorescence in situ hybridization or
conventional cytogenetics [21].
Statistical Analysis
To obtain an unbiased comparison of the 2 arms, patients were
randomized using the Pocock-Simon dynamic allocation method [22] to
achieve balance with regard to 2 binary prognostic covariates: chemo-
sensitivity (yes or no) and donor type ([MUD or matched sibling donor
[MSD]). An extension of the method of Thall and Sung [23] was used to
comparativelymonitor the probabilities of death and 100-day success (alive,
responding, and engrafted at day 100) between the 2 arms, with rules for
stopping the trial early if either event occurred at substantially different
rates in the 2 arms. The sample size was determined by practical consid-
erations and accrual limitations, and the results cannot be considered
conﬁrmatory.
We evaluated 3 binary outcomes: ﬁnal response (complete response
[CR] or very good partial response [VGPR]), acute GVHD status (deﬁned as
GVHD with maximum grade 2), and any grade 3, 4, or 5 toxicity (“severe
toxicity”). For the ﬁnal response and severe toxicity analyses, 50 patients’
datawere included. For the acute GVHD analysis, only 48 patients’ datawere
available. A multivariate logistic regression model [24] was ﬁt to identify
important predictors for each binary outcome. From these ﬁtted models, we
estimated the odds ratio for each potential prognostic factor with a 95%
conﬁdence interval.
Patient characteristics were summarized using the mean and standard
deviation for numerical valued variables and frequencies with percentages
for categorical variables. Differences in the distributions of patient charac-
teristics between the 2 treatment groups and associations between variables
were assessed using the Wilcoxon rank sum test for numerical variables or
generalized Fisher exact tests for categorical variables [25,26]. Unadjusted
probabilities of OS, PFS, and TRM time were estimated using the method of
Kaplan and Meier [27]. The log-rank test [28] was used to compare unad-
justed OS and PFS between subgroups. The Cox proportional hazards
regression model was used to assess association between potential prog-
nostic factors and each time-to-event outcome. This modeling included all
important covariates, without performing variable selection. For each ﬁtted
model, we estimated the hazard ratio for the prognostic factor with a 95%
conﬁdence interval. The Cox proportional hazards [29] assumption was
assessed using the Grambsch-Therneau goodness-of-ﬁt test [30]. All anal-
yses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC) and R
version 2.11.1 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patients
The patient and disease characteristics are summarized in
Table 1. Of the 50patients, all but 2 had received at least 1 auto-
HCT and 80% of patients had experienced at least 1 relapse
before allo-HCT. There was no signiﬁcant difference in age,
high-risk cytogenetic features, interval from diagnosis to
allo-HCT, percentageof plasmacells in thebonemarrowatallo-
HCT, or number of auto-HCT between the 2 groups. Signiﬁ-
cantly more patients in the FM100 arm had MSD allo-HCT
versus the FM140 arm, 91% versus 56%, respectively (P ¼ .01).
Engraftment and Toxicity
All patients engrafted with a median time to neutrophil
engraftment of 12 days in both treatment arms (P¼ .21). The
median time to platelet engraftment was 12.5 and 13 days
in the FM100 and the FM140 arms, respectively (P ¼ .27).
Grade III and IV nonhematologic toxicities were seen in 82%
(n ¼ 19) and 85% (n ¼ 23) of patients in the FM100 and the
FM140 arms, respectively (P ¼ 1.0). The incidence of grade II
to IV gastrointestinal toxicity, mucositis, and culture-proven
infections was higher in the FM140 arm; however, only
Table 2
Nonhematological Toxicity in FM100 and FM140 Arms
Toxicity FM100 FM140 P Value
Grade III to IV (total) 19 (82) 23 (85) 1.00
Gastrointestinal (grade II to IV) 10 (44) 20 (74) .04
Nausea (grade II to IV) 5 (22) 16 (59) .01
Diarrhea (grade II to IV) 5 (22) 7 (26) 1.00
Mucositis (grade II to IV) 2 (9) 7 (26) .15
Renal insufﬁciency (grade II to IV) 5 (22) 3 (11) .44
Infections*,y (grade II to IV) 10 (44) 15 (56) .57
Pulmonary edema (grade II to IV) 0 3 (11) .23
Veno-occlusive disease 0 0 1.00
F indicates ﬂudarabine; M, melphalan.
Data are presented as n (%) unless otherwise indicated.
* Only culture-proven infections.
y In addition to culture-proven infections, 2 patients (9%) in FM100 and 4
patients (15%) in FM140 arms had suspected pneumonia empirically treated
with antibiotics.
Table 1
Patient and Disease Characteristics
Characteristic FM100 FM140 P
Value
No. of patients 23 27
Age, median (range), yr 53 (36 to 64) 52 (32 to 64) .21
Sex .15
Female 12 (52) 8 (30)
Male 11 (48) 19 (70)
High-risk cytogenetics .77
Total 8 (35) 11 (41)
Del 13 4 (17) 3 (11)
Del 13 þ t(4;14) 1 (4) 1 (4)
Del 13 þ hypodiploid 2 (9) 1 (4)
Del 13 þ t(14;16) 0 1 (4)
Del 13 þ Del 17p 0 2 (7)
Hypodiploid 1 (4) 0
Del 17p 0 1 (4)
Del 13 þ Del 17p þ
hypodiploid
0 2 (7)
Prior auto-HCT 21 (91) 27 (100) .20
No. of prior auto-HCT,
median (range)
1 (0 to 2) 1 (1 to 3) .09
Time between auto-HCT
and allo-HCT, median
(range), mo*
17 (2.4 to 60) 12 (2.4 to 60) .31
Disease status at allo-HCT .02
CR 0 (0) 1 (4)
VGPR 6 (26) 4 (15)
PR 9 (39) 13 (48)
<PR 8 (35) 3 (11)
PD 0 (0) 6 (22)
Disease status at allo-HCT .73
CR þ VGPR 6 (26) 5 (19)
Interval from diagnosis
to allo-HCT, median
(range), mo
34.6 (11.6 to 232) 30.7 (6.6 to 191) .56
Stem cell source .19
Bone marrow 1 (4) 5 (19)
Peripheral blood 22 (96) 22 (81)
Donor type .01
Matched sibling 21 (91) 15 (56)
Matched unrelated 2 (9) 12 (44)
Rituximab .41
No 14 (61) 13 (48)
Yes 9 (39) 14 (52)
Maintenance therapy 3 (13) 5 (16) .71
F indicates ﬂudarabine; M, melphalan; Auto-HCT, autologous hematopoietic
stem cell transplantation; Allo-HCT, allogeneic hematopoietic stem cell
transplantation; CR, complete response; VGPR, very good partial response;
PR, partial response; PD, progressive disease.
Data are presented as n (%) unless otherwise indicated.
* For the entire group, the median time interval between auto-HCT and
allo-HCT was 15.6 months (range, 2.4 to 60).
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(Table 2).
Among 50 patients in the OS analysis, 29 (58%) patients
died: 12 (52%) in the FM100 arm and 17 (63%) in the FM140
arm. One-year TRM was 13% (n ¼ 3; 1 acute GVHD, 1 liver
failure, and 1 idiopathic pneumonia syndrome) and 15% (n ¼
4; 2 acute GVHD, 1 chronic GVHD, 1 unknown) in the FM100
and the FM140 arms, respectively (P ¼ 1.0). On multivariate
analysis, the melphalan dose intensity, high-risk cytoge-
netics, disease status at allo-HCT, interval from diagnosis to
allo-HCT, rituximab use, or the donor type did not signiﬁ-
cantly impact TRM.GVHD
Grade I acute GVHDwas seen in 8 patients (34%) in FM100
and 12 patients (44%) in FM140 (P ¼ .56). Grade II acute
GVHD was seen in 5 patients (21%) in FM100 and 6 patients(22%) in FM140 (P ¼ .56). Grades III or IV acute GVHD were
seen in 1 patient (4%) in FM100 and 6 patients (22%) in
FM140 (P ¼ .10). Chronic GVHD was seen in 11 patients (48%)
in FM100 and 8 patients (29%) in FM140 (P ¼ .24). On
multivariate analysis, no signiﬁcant association was seen
between the risk of developing acute GVHD and the
melphalan dose intensity, cytogenetic risk proﬁle, disease
status at allo-HCT, interval from diagnosis to allo-HCT,
rituximab use, or donor type (data not shown).
Disease Response
The overall response rate was 83% (CR, 26%; VGPR, 22%;
partial response [PR], 35%) in patients assigned to FM100 and
82% (CR, 26%; VGPR, 26%; PR, 30%) in patients assigned to
FM140 (P ¼ .99). The response rate was 67% (CR, n ¼ 1; VGPR
n ¼ 1; PR n ¼ 2) in 6 patients who had progressive disease
(PD) at the time of allo-HCT. All these patients were in the
FM140 arm. The percentage of patients with PD [31] after
allo-HCT was also similar in both treatment groups (9% in
FM100 and 11% in FM140, P ¼ .99).
Survival and Progression
The median follow-up in all patients was 16.8 months
(range, 1.7 to 91.5 months). The median PFS in the entire
group was 10.1 months. The median PFS was 11.7 and 8.4
months in the FM100 and the FM140 arms, respectively (P ¼
.12) (Figure 1A). The 2-year PFS was 41% versus 24% in the
FM100 and the FM140 arms, respectively (P ¼ .12)
(Figure 1A). The median OS in the entire group was 25.7
months. The median OS in the FM100 and the FM140 arms
was 35.1 and 19.7 months, respectively (P ¼ .38) (Figure 1B).
The 2-year OS was 63% versus 45% in the FM100 and the
FM140 arms, respectively, (P ¼ .38) (Figure 1B). After
excluding 6 patients from the FM140 armwho had PD at the
time of allo-HCT, the median PFS was 11.9 and 9.1 months
(P¼ .25) and the OSwas 35.7 and 30.0months (P¼ .60) in the
FM100 and the FM140 arms, respectively. Among the 6
patients with PD at the time of allo-HCT, 2 were alive at the
time of last follow-up. The median PFS and OS in these 6
patients were 4 and 4.9 months, respectively. On multivar-
iate analysis, the disease status at allo-HCT, CR, or VGPR, was
associated with signiﬁcantly longer PFS (15.9 months)
compared with the patients who had <VGPR, in whom the
PFS was 8.9 months (P ¼ .05). In addition, a trend toward
longer PFS was seen in recipients of MSD allografts compared
with the recipients of MUD allografts, 11.6 versus 8.1 months,
respectively (P ¼ .07). The melphalan dose intensity,
Table 3
Multivariate Cox Proportional Hazards Model for PFS and OS
Variable Median
PFS, mo
P Value Median
OS, mo
P Value
Overall (n) 10.1 25.7
Conditioning regimen
FM100 (23) 11.7 .12 35.1 .38
FM140 (27) 8.4 19.7
Rituximab
No (27) 10 .82 25.7 .81
Yes (23) 11.2 -
Donor
Matched sibling (36) 11.6 .07 29.6 .13
Matched unrelated
(14)
8.1 10.8
Chemo-sensitive disease
at transplantation
No (8) 25.6 .28 25.7 .56
Yes (42) 9.5 20.2
High-risk cytogenetics
No (31) 11.73 .10 25.7 .64
Yes (19) 8.1 19.7
Prior response
<VGPR (39) 8.9 .05 20.3 .21
VGPR (11) 15.9 47.8
PFS indicates progression-free survival; OS, overall survival; F, ﬂudarabine;
M, melphalan; VGPR, very good partial response.
Figure 1. (A) Progression-free survival (PFS) by treatment group. (B) Overall
survival (OS) by treatment group.
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or rituximab use did not signiﬁcantly impact PFS. No differ-
ence in OS was seen across all variables (Table 3).
Thirty-nine (78%) patients either experienced disease
progression or died by the end of the study. Among these, 15
(65%) were in the FM100 group, and 24 (89%) were in the
FM140 arm. The cumulative incidence rates of disease
progression in FM100 and FM140 were 43% (n ¼ 10) and 70%
(n¼ 19), respectively (P¼ .08). Eight patients (3 in FM100 and
5 in FM140) received donor-lymphocyte infusions. The
outcomes of these patients were not separately analyzed.
Recurrent disease was the most common cause of death in
both FM100 (26%) and FM140 (44%) treatment arms (P¼ .24).DISCUSSION
Although the melphalan dose is relatively well charac-
terized in auto-HCT conditioning [32], there is no consensus
regarding dosing before allo-HCT, and different doses are
used across transplantation centers [4,33]. The melphalan
dose of 140 mg/m2 or less is generally considered non-
myeloablative [4]; however, it is not entirely clear if reducingthe dose to 100 mg/m2 will adversely affect the trans-
plantation outcomes. This study is the ﬁrst prospective trial
that randomized the patients to 2 reduced-intensity regi-
mens consisting of melphalan (100 mg/m2 or 140 mg/m2) in
combination with ﬂudarabine before allo-HCT. Our results
indicate that FM100 is at least as effective as FM140 and the
melphalan dose reduction does not compromise trans-
plantation outcomes.
The results of allo-HCT are superior when it is performed
earlier in the course of disease versus after relapse [34].
Several large randomized trials have compared tandem auto-
HCT with auto-HCT followed by RIC allo-HCT in patients with
newly diagnosed myeloma. Overall, 2 randomized trials have
shown that auto-HCT followed by RIC allo-HCT leads to
superior PFS andOS [35,36]. Themajorityof other randomized
trials, however, showed that although allo-HCT is associated
with a superior CR rate, the PFS and OS are similar to tandem
auto-HCT [37-40]. The TRM is generally higher with allo-HCT
and it is conceivable that reducing early TRM will lead to
improved outcomes with allo-HCT. The TRM in our study was
15% in both treatment arms,which is similar to that reported
in studies of allo-HCT in newly diagnosed myeloma patients.
This highlights the feasibility of this treatment modality in
patients with heavily pretreated myeloma.
In the salvage setting, auto-HCT remains an effective
treatment option. In a recent study that evaluated the
outcome of second auto-HCT for relapsed disease, the
median PFS and OSwere 9.8 and 17.3months, respectively, in
patients who relapsed 24 months after initial auto-HCT
[41]. Similarly, in a registry analysis of second auto-HCT for
relapsed myeloma, the 3-year PFS and OS were 13% and 46%,
respectively [42]. In another study, Mehta et al. compared the
outcome of salvage auto-HCT with salvage allo-HCT [43]. The
3-year event-free survival was similar in both groups, but the
3-year probability of OS was higher after auto-HCT. However,
the TRM after allo-HCT in this study was signiﬁcantly higher
(43% 8% versus 10% 5% with auto-HCT). Furthermore, the
patients in the allo-HCT group were older, had higher
b2-microglobulin, and had a shorter interval between the
2 transplantations. In our data, the median time between
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aggressiveness of myeloma and the fact that a majority of
patients had relapsed or refractory disease before allo-HCT.
Overall, our results compare favorably with the published
data of auto-HCT for relapsed myeloma; however, random-
ized studies are required to properly address this question.
The disease status at the time of allo-HCT is 1 of the most
important determinants of treatment outcome [34,44]. The
patients in<VGPR at allo-HCT had a signiﬁcantly shorter PFS
and a shorter OS (20.4 versus 48 months in patients with
VGPR), which was not statistically signiﬁcant, probably
because of our short follow-up. Overall, our data conﬁrm that
better disease control before allo-HCT can signiﬁcantly
prolong survival.
One of the major concerns of RIC regimens is the
increased risk of relapse [4]. We did not see a signiﬁcant
difference in relapse risk between the 2 arms. Interestingly,
there was a trend toward lower relapse rate in the FM100
arm compared with the FM140 arm, 43% versus 70%,
respectively. The reason for this trend is not entirely clear.
One speculation is that signiﬁcantly more patients in the
FM100 arm received a transplant fromMSDs (91%) compared
with patients in the FM140 arm (56%), and there was a trend
toward improved PFS in recipients of MSD allografts
compared with MUDs. Furthermore, development of chronic
GVHD is associated with lower risk of relapse [45,46], and
a higher proportion of chronic GVHD was observed in the
FM100 arm (48% versus 29% in FM140). A possible explana-
tion of higher chronic GVHD rate in the FM100 arm is that
only 9% of patients received ATG compared with 44% in the
FM140 arm, as ATG was given only to the recipients of MUD
allografts.
Another important determinant of outcome after allo-HCT
in myeloma patients is the presence or absence of high-risk
chromosomal features [34,47,48]. The emerging data suggest
that the novel agents, particularly bortezomib, can at least
partially overcome the negative impact of high-risk features
[49]. Nevertheless, the patients carrying these high-risk
chromosomal abnormalities continue to have poorer prog-
nosis compared with the patients who lack such abnormali-
ties [50,51]. Allo-HCT may have a role in these high-risk
patients. However, prospective studies have yet to show
a beneﬁt with allo-HCT, perhaps because of the small number
of patients with high-risk abnormalities in these studies.
Some retrospective analyses, however, suggest that patients
carrying 1 ormore high-risk chromosomal abnormalitiesmay
beneﬁt from allo-HCT [47]. In our study, the presence of 1 or
more high-risk abnormalities was not associated with poor
PFS or OS. Although these results are encouraging, we cannot
conclude that RIC allo-HCT with ﬂudarabine/melphalan (FM)
can overcome the poor prognostic impact of these abnor-
malities. Perhaps the limited number of patients precludes
any deﬁnite conclusions. However, our results suggest a role
for allo-HCT to be explored in high-risk myeloma patients in
well-designed clinical trials.
Several groups have reported their experience of RIC allo-
HCT with FM regimen [37,52-55]. In the setting of newly
diagnosed myeloma, 2 large prospective trials of allo-HCT
with FM conditioning following initial auto-HCT have been
reported [37,54]. FM140 with or without ATG was used in
both trials. There was a trend for longer PFS in the PETHEMA
study compared with tandem auto-HCT [37]; however, OS
was similar in both studies. Others have reported the feasi-
bility of FM conditioning for patients with relapsed/refrac-
tory myeloma [52,53,56]. In a prospective study by Krogeret al., the FM140 regimen was used for pretransplantation
conditioning in 49 patients who had relapsed after an auto-
HCT [53]. Forty-three percent patients had <PR at allo-HCT.
The response rate was 95%, and TRM for a fully matched
donor HCT was 10%. The median PFS and OS for a fully
matched donor HCT were 13 and 32 months, respectively.
Nine patients in this study received FM100; however, their
outcomes were not separately analyzed. In another report,
Shimoni et al. retrospectively analyzed the outcome of 50
myeloma patients with relapsed/refractory disease who
received RIC allo-HCT after the FM (100 to 150) conditioning
[56]. The TRM was 26% and the median time to progression
was 9 months. Overall, the outcome of patients in our study,
where 80% of patients had experienced at least 1 relapse
before allo-HCT, is comparable to the other studies that
primarily used FM conditioning.
Our study has several limitations, including a limited
number of patients precluding a comprehensive analysis of
various risk factors. There is heterogeneity in both treatment
arms with more patients receiving allografts fromMSDs, less
use of ATG, and a higher incidence of cGVDH in the FM100
group as well as a higher number of patients receiving MUD
allografts and with PD in the FM140 group. It was not
possible to balance randomization perfectly on all covariates
with this sample size. A larger phase III study is required to
address these issues.
In summary, our data suggest that FM100 and FM140 are
both effective regimens, and reducing the melphalan dose to
100 mg/m2 may not adversely impact the response or
remission duration. FM100 may provide the framework to
build safer and more effective preparative regimens for allo-
HCT for myeloma.ACKNOWLEDGMENTS
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